Exploring two clinical-stage firms with new, different approaches to treatments
June 27, 2018
0
SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in Phase 2 clinical trial for the treatment of localized prostate. The product is in Phase 3 clinical trial for lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a first-in-class, pore-forming protein activated only with the enzymatic action of PSA, which is found in high concentrations around …